Study type: Observational(clinical trial); estimated enrolments: 80 patients (40 conventional CRS, 40 fluorescence-guided CRS: 20 ICG, 20 ICM-137); Intervention: Half of the patients undergoing complete CRS must be evaluated with fluorescence, the aim is to determine the percentage of undetected peritoneal metastasis; After complete FG CRS random biopsies will be taken from the remaining ”normal looking peritoneum”; Patients will be randomized according to KRAS status to be in the standard, the Fluo-ICG or the Fluo-EMI-137 arm. Here, KRAS is linked to congenital rubella syndrome.